Added to YB: 2024-10-04
Pitch date: 2024-10-04
GMAB [neutral]
Genmab A/S
+33.4%
current return
Author Info
Quality Stocks helps you find valuable insights to become a better investor, discover quality companies, and find investment ideas. Sign up for the newsletter.
Company Info
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Market Cap
DKK 19.5B
Pitch Price
DKK 23.47
Price Target
N/A
Dividend
N/A
EV/EBITDA
10.89
P/E
12.61
EV/Sales
4.22
Sector
Biotechnology
Category
growth
Genmab A/S (GMAB) Faces High Stakes as Darzalex Dominates Revenue and Pipeline Uncertainty Persists
GMAB (quick dive): Blockbuster Darzalex (68% H1 2024 rev) drives growth; strong pipeline & balance sheet. Risks: pipeline uncertainty, cash needs, Darzalex patent expiry 2029. 20x P/E. Conservative avoid, moderate wait for Q3/1400 DKK support, aggressive bet on Phase III success.
Read full article (1 min)